Tuberculosis during TNF-α inhibitor therapy, despite screening
- PMID: 23598710
- DOI: 10.1136/thoraxjnl-2012-202974
Tuberculosis during TNF-α inhibitor therapy, despite screening
Abstract
As part of a prospective study on the safety of TNF-α inhibitor therapy after screening for and treatment of latent tuberculosis infection (LTBI), we report two patients who developed active tuberculosis (TB) infection during TNF-α inhibitor therapy, despite negative screening for LTBI. The clinical history is suggestive of a primary infection acquired during travelling to TB-endemic countries. In this lesson of the month we would like to highlight the risk of travelling to TB-endemic areas in patients treated with TNF-α inhibitor therapy. Screening for latent tuberculosis infection is not enough to prevent tuberculosis in patients treated with TNF-α inhibitor therapy.
Keywords: Immunodeficiency; Infection Control; Respiratory Infection; Tuberculosis.
Comment in
-
Letter in response to TB during TNF-α inhibitor therapy, despite screening.Thorax. 2015 Apr;70(4):373. doi: 10.1136/thoraxjnl-2014-206239. Epub 2014 Oct 29. Thorax. 2015. PMID: 25354515 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials